evandro.deazambuja@medenrich.com

About

Dr. Evandro de Azambuja is Medical Oncologist focused on breast cancer therapy and is involved practice changing phase III trials in breast cancer like as HERA (adjuvant trastuzumab), ALTTO (trastuzumab and/or lapatinib), APHINITY (trastuzumab with or without pertuzumab), Olympia (adjuvant Olaparib) to name a few. He has (co)-authored around 255 articles and 15 book chapters in peer reviewed publications. He has been a member of the Education and Scientific Committees of the ESMO Congress, ESMO Breast, EBCC and ECCO meetings.